OUR MEDICAL RESPONSE

A noninvasive medical device to treat CAS with ultrasounds

To treat CAS, Cardiawave has developed a noninvasive approach using ultrasounds consisting in repairing the aortic valve, not replacing it. No surgery is required.

Our new ultrasound therapy involves delivering an extremely precise and focused ultrasound beam to perform a remote and reparative effect on the aortic valve. We soften the cardiac tissues and enable the aortic valve to open widely again. We restore leaflet mobility.

Our Valvosoft device is both an imaging and therapy device. It is applied directly on the patient’s chest, over the beating heart.

Cardiawave provides a unique solution to an unmet medical need.

BENEFITS AND ADVANTAGES

Our therapy has many advantages:

  • Patients affected and not eligible to current surgery will benefit from our treatment
  • The treatment is noninvasive and can be repeated
  • Our device will decrease morbidity rates, risks and complications
  • It will improve the quality of life of patients
  • The cost will be reduced for healthcare system and private insurers
  •  We intend to use our device as preventive medicine to slow the progression of CAS

TODAY

WITH THE CURRENT MEDICAL RESPONSE

PATIENTS WITH NO MEDICAL RESPONSE

Invasive treatment

Valve replacement

24-26% morbidity at 1 year – Risks and complications

OVERALL ACTUAL COST PER PROCEDURE: FROM €50 TO €80K

TOMORROW

THANKS TO CARDIAWAVE

NEW ELIGIBLE PATIENTS – PREVENTIVE TREATMENT FORESEEABLE

Noninvasive treatment

Repair of native valves

EXPECTED MORBIDITY ~0% – QUALITY OF LIFE IMPROVEMENT

DECREASE OF COST PER PROCEDURE

AN UNDERLYING DISRUPTIVE TECHNOLOGY

The disruptive and patented technology developed by Cardiawave is unique and offers several advantages over state-of-the-art and all existing technologies. It allows physicians to deliver with a noninvasive medical device mechanical energy on a moving target with millimetric precision, while at the same time preserving the tissue and organs through which the ultrasound passes. Unlike any existing technology, it is possible to target and treat, almost simultaneously, several anatomical zones spread over a large area without physically moving the medical device, which is placed on the patient’s chest. Treatment and its effects are monitored in real time.